Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
Conditions
Interventions
Intervention1: pentoxifylline: 400 mg per dose, thrice- daily dosing, administered for seven days, to be consumed orally after food
Control Intervention1: Standard of Care: As per Standard of Care for
Sponsors
Dr Subhash Gupta
Eligibility
Inclusion criteria
Inclusion criteria: Adult male or female patients, with proven COVID-19 moderate disease with any one of respiratory rate 24- 30/min, breathlessness, SPO2 90-93% on room air will be included in the study.
Exclusion criteria
Exclusion criteria: (a) Children 70 years (b) Pregnancy & lactation (c) History of GI bleeding (d) History of Seizures, Cardiac or other vascular stents (e) History of intracranial hemorrhage (f) Patients with recent cerebral and/or retinal hemorrhage/ intracranial haemorrhage (g) Pts with serum ALT/AST > 5 times the upper limit of normal (h) In patients who have previously exhibited intolerance to this product
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| we will evaluate the impact of addition of tablet Pentoxifylline to conventional treatment in patients with moderate COVID -19 disease on reduction in need for invasive ventilation (IV) i.e. intubation and mechanical ventilation. Lesser number of patients with moderate COVID disease on WHO ordinal scale 4 ( i.e those who require oxygen therapy through face mask/ nasal prongs) would deteriorate to WHO Ordinal scale 6 (i.e. those needing intubation and mechanical ventilation)Timepoint: 28 days | — |
Secondary
| Measure | Time frame |
|---|---|
| addition of trial drug an ICU admissionTimepoint: 28 days | — |
Countries
India
Contacts
Public ContactDr Shweta A Singh
Max Super Speciality Hospital
Outcome results
None listed